Please assess the completion status of the following clinical trial:

Trial Title: S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically proven newly diagnosed single, primary, bronchogenic stage IIIA or selected stage IIIB (excluding malignant pleural effusion) non-small cell lung cancer (NSCLC) of one of the following cellular types:~  * Adenocarcinoma~ * Large cell carcinoma~ * Squamous cell carcinoma~ * Unspecified~* Histology or cytology from involved mediastinal or supraclavicular nodes will be sufficient for diagnosis if a separate primary lesion of the lung parenchyma is clearly evident on radiographs (i.e., a second biopsy will not be required)~* Underwent positron emission tomography (PET) scan within the past 42 days~  * N2 or N3 mediastinal disease by PET scan OR enlarged nodes on CT scan determined to be N2 or N3 by biopsy~* Measurable disease, defined as lesions that can be accurately measured in at least one dimension as ≥ 2 cm by conventional techniques or ≥ 1 cm by spiral CT scan~  * Pleural effusion, ascites, bone lesions, and laboratory parameters are not considered measurable disease~* No brain metastases~* Malignant pleural effusion allowed provided 1 of the following is true:~  * Present before mediastinoscopy or exploratory thoracotomy AND the pleural fluid is transudate with negative cytology~ * Present only after but not before exploratory or staging thoracotomy AND the pleural fluid is either transudate or exudate with negative cytology~ * Present only on CT scan but not on decubitus chest x-ray AND deemed too small to tap under either CT scan or ultrasound guidance~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1, meeting ≥ 1 of the following criteria OR Zubrod performance status 2 with no co-morbidities or meeting 1 of the following criteria:~  * No co-morbidities~ * FEV_1 \< 2 L OR \< 1 L with estimated contralateral FEV_1 ≥ 0.6 L~ * DLCO \> 10 mL/mm Hg/min~ * Albumin \< 0.85 times lower limit of normal~ * Unintentional weight loss \> 10% within the past 6 months~ * Controlled congestive heart failure which, in the opinion of the investigator, may become decompensated due to radiotherapy~* FEV_1 \< 2 L OR \< 1 L with estimated contralateral FEV_1 ≥ 0.6 L~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* Must provide prior smoking history~* Serum bilirubin normal~* Meets one of the following criteria:~  * Alkaline phosphatase (AP) ≤ 4 times ULN AND SGOT or SGPT normal~ * AP normal AND SGOT or SGPT ≤ 2.5 times ULN~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission~* No pregnant or nursing patients~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or curative surgery for this cancer~* No prior radiotherapy to the neck and/or thorax for any reason~* No prior therapy which specifically targets the EGFR pathway~* No concurrent growth factors (e.g., filgrastim \[G-CSF\], epoetin alfa, or pegfilgrastim) or amifostine~* No concurrent intensity-modulated radiotherapy~* No concurrent prophylactic mediastinal, contralateral hilar, or supraclavicular lymph node radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Radiotherapy (no Docetaxel) (Type: EXPERIMENTAL): None
- Cetuximab + Radiotherapy + Docetaxel (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).